Office of Biotechnology Activities, Office of Science Policy, Office of the Director; Notice of Meeting, 6193-6194 [08-440]
Download as PDF
Federal Register / Vol. 73, No. 22 / Friday, February 1, 2008 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: January 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–437 Filed 1–31–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on PROD1PC66 with NOTICES
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group, Microbiology and Infectious Diseases
Research Committee.
Date: February 28–29, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza Hotel, 8777 Georgia
Ave., Silver Spring, MD 20910.
Contact Person: Annie Walker-Abbey, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIH/NIAID/DHHS, 6700B Rockledge Drive,
Rm. 3126, Bethesda, MD 20892–7616, (301)
451–2671, aabbey@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–439 Filed 1–31–08; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005
18:22 Jan 31, 2008
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel, Environmental Factors in
Neurodegenerative Diseases.
Date: February 25–27, 2008.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Durham/
SouthPoint, 7007 Fayetteville Road, Durham,
NC 27713.
Contact Person: Leroy Worth, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research and Training, Nat. Institute of
Environmental Health Sciences, P.O. Box
12233, MD EC–30/Room 3171, Research
Triangle Park, NC 27709, (919) 541–0670,
worth@niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel, Molecular Biomarkers
Related to Cancer.
Date: February 26, 2008.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIEHS/National Institutes of Health,
Building 4401, East Campus, 79 T.W.
Alexander Drive, Research Triangle Park, NC
27709. (Telephone Conference Call).
Contact Person: Sally Eckert-Tilotta, PhD,
Scientific Review Administrator, Nat.
Institute of Environmental Health Sciences,
Office of Program Operations, Scientific
Review Branch, P.O. Box 12233, Research
Triangle Park, NC 27709, (919) 541–1446,
eckertt1@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
6193
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: January 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–444 Filed 1–31–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of Biotechnology Activities,
Office of Science Policy, Office of the
Director; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
National Science Advisory Board for
Biosecurity (NSABB).
Under authority 42 U.S.C. 217a,
section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
NSABB to provide advice, guidance and
leadership regarding federal oversight of
dual use research, defined as biological
research with legitimate scientific
purposes that could be misused to pose
a biological threat to public health and/
or national security.
The meeting will be open to the
public, however, pre-registration is
strongly recommended due to space
limitations. Persons planning to attend
should register online at https://
www.biosecurityboard.gov/meetings.asp
or by calling Capital Consulting
Corporation (Contact: Saundra
Bromberg at (301) 468–6004, ext. 406).
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
indicate these requirements upon
registration.
Name of Committee: National Science
Advisory Board for Biosecurity.
Date: February 27–28, 2008.
Open: 8:30 a.m. to 5:30 p.m.
Agenda: Presentations and discussions
regarding: (1) United States Government
consideration of NSABB policy
recommendations; (2) strategies regarding
Outreach and Education; (3) report on second
International Roundtable and update on
International Working Group; (4) public
comments; and (5) and other business of the
Board.
Place: The National Institutes of Health, 31
Center Drive, Building 31, C Wing, 6th Floor,
Rooms 6–10, Bethesda, Maryland 20892.
E:\FR\FM\01FEN1.SGM
01FEN1
6194
Federal Register / Vol. 73, No. 22 / Friday, February 1, 2008 / Notices
Contact Person: Ronna Hill, NSABB
Program Assistant, 6705 Rockledge Drive,
Bethesda, Maryland 20892, (301) 496–9838.
This meeting will also be Web cast. The
draft meeting agenda and other information
about NSABB, including information about
access to the Web cast and pre-registration,
will be available at https://
www.biosecurityboard.gov/meeting.asp.
Please check the OBA Web site for updates.
Times are approximate and subject to change.
Any member of the public interested in
presenting oral comments at the meeting may
notify the Contact Person listed on this notice
at least 10 days in advance of the meeting.
Interested individuals and representatives of
an organization may submit a letter of intent,
a brief description of the organization
represented and a short description of the
oral presentation. Only one representative of
an organization may be allowed to present
oral comments. Both printed and electronic
copies are requested for the record. In
addition, any interested person may file
written comments with the committee. All
written comments must be received by
February 20, 2008 and should be sent via email to nsabb@od.nih.gov with ‘‘NSABB
Public Comment’’ as the subject line or by
regular mail to 6705 Rockledge Drive, Suite
750, Bethesda, MD 20892, Attention Ronna
Hill. The statement should include the name,
address, telephone number and, when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Dated: January 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–440 Filed 1–31–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
mstockstill on PROD1PC66 with NOTICES
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
VerDate Aug<31>2005
18:22 Jan 31, 2008
Jkt 214001
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Pub. L. 100–
71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840 / 800–877–7016. (Formerly:
Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770 / 888–290–
1150.
Aegis Sciences Corporation, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400. (Formerly: Aegis Analytical
Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
Rock, AR 72205–7299, 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
Diagnostic Services, Inc., dba DSI,
12700 Westlinks Drive, Fort Myers,
FL 33913, 239–561–8200 / 800–735–
5416.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310.
Dynacare Kasper Medical Laboratories*,
10150–102 St., Suite 200, Edmonton,
Alberta, Canada T5J 5E2, 780–451–
3702 / 800–661–9876.
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.
Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053, 504–
361–8989 / 800–433–3823. (Formerly:
Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc., 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130. (Formerly:
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288 /
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400 / 800–437–
4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900 / 800–833–3984.
E:\FR\FM\01FEN1.SGM
01FEN1
Agencies
[Federal Register Volume 73, Number 22 (Friday, February 1, 2008)]
[Notices]
[Pages 6193-6194]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 08-440]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of Biotechnology Activities, Office of Science Policy,
Office of the Director; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of
the National Science Advisory Board for Biosecurity (NSABB).
Under authority 42 U.S.C. 217a, section 222 of the Public Health
Service Act, as amended, the Department of Health and Human Services
established NSABB to provide advice, guidance and leadership regarding
federal oversight of dual use research, defined as biological research
with legitimate scientific purposes that could be misused to pose a
biological threat to public health and/or national security.
The meeting will be open to the public, however, pre-registration
is strongly recommended due to space limitations. Persons planning to
attend should register online at https://www.biosecurityboard.gov/
meetings.asp or by calling Capital Consulting Corporation (Contact:
Saundra Bromberg at (301) 468-6004, ext. 406). Individuals who plan to
attend and need special assistance, such as sign language
interpretation or other reasonable accommodations, should indicate
these requirements upon registration.
Name of Committee: National Science Advisory Board for
Biosecurity.
Date: February 27-28, 2008.
Open: 8:30 a.m. to 5:30 p.m.
Agenda: Presentations and discussions regarding: (1) United
States Government consideration of NSABB policy recommendations; (2)
strategies regarding Outreach and Education; (3) report on second
International Roundtable and update on International Working Group;
(4) public comments; and (5) and other business of the Board.
Place: The National Institutes of Health, 31 Center Drive,
Building 31, C Wing, 6th Floor, Rooms 6-10, Bethesda, Maryland
20892.
[[Page 6194]]
Contact Person: Ronna Hill, NSABB Program Assistant, 6705
Rockledge Drive, Bethesda, Maryland 20892, (301) 496-9838.
This meeting will also be Web cast. The draft meeting agenda and
other information about NSABB, including information about access to
the Web cast and pre-registration, will be available at https://
www.biosecurityboard.gov/meeting.asp. Please check the OBA Web site
for updates. Times are approximate and subject to change.
Any member of the public interested in presenting oral comments
at the meeting may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of an organization may submit a letter of
intent, a brief description of the organization represented and a
short description of the oral presentation. Only one representative
of an organization may be allowed to present oral comments. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee. All written comments must be received by February 20,
2008 and should be sent via e-mail to nsabb@od.nih.gov with ``NSABB
Public Comment'' as the subject line or by regular mail to 6705
Rockledge Drive, Suite 750, Bethesda, MD 20892, Attention Ronna
Hill. The statement should include the name, address, telephone
number and, when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Dated: January 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-440 Filed 1-31-08; 8:45 am]
BILLING CODE 4140-01-M